NECTIN4

Across TCGA pan-cancer cohorts, NECTIN4 Mutation is linked to patient survival in 5 of 34 cancer types, making it a survival-associated NECTIN4 data layer compared with 26 for mass-spec protein and 4 for mass-spec protein.

The strongest signal is observed in lung adenocarcinoma (LUAD), where higher NECTIN4 Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated NECTIN4 expression acts as an unfavorable survival marker.

LUAD, BLCA, and SCLC are the cancer types where NECTIN4 Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
LUAD	OS	Median	III,IV	0.068	0.680	<.001	22	view →
BLCA	DFS	Median	II,III,IV	0.156	0.627	.001	18	view →
SCLC	OS	Median	All	0.082	0.708	<.001	12	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
COAD	OS	Median	All	0.113	0.806	<.001	6	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

NECTIN4–LUAD (OS)

Open the LUAD breakdown →